Table 2.

HBV Markers Among Subjects With Incident (Patient CUI-125) or Possible Incident (Patients CUI-156 and CUI-218) HBV Infection^a

Marker	CUI-125 (Female, Aged 29)b Week							CUI-156 (Male, Aged 54) Week						CUI-218 (Female, Aged 65) Week
	0	4	12	24	26	36	105	0	4	12	24	36	48	0	4	12	24	36	48
HBsAg	-	-	+++	++++	-	-	-	-			-	++	+	-		-	-	-
Anti-HBs	-						-	+			++		+	+		+		+++
Anti-HBc	-		-				+	-	-	-	+		+	-		-	-	++
Anti-HBe	-		-	-			-	-			-		-	-		-		+
HBV DNA	-	-	++++	+++++			-	-	-	-	-		-	-		-	+	+
AST U/L	19	23	19	661				27	30	41	42	37	31	36	21	21	23	19	102
ALT U/L	28	12	20	824				27	21	35	59	39	44	20	16	18	19	16	109
HIV-1 RNAc	UD		UD	UD				UD		UD	UD	UD	UD	UD		UD	105	UD
CD4 countd	340			426				338			268		337	535			667		674
NRTIs	TDF 3TC	None	None	None	TDF 3TC	TDF 3TC	TDF 3TC	TDF 3TC	None	None	None	None	None	TDF 3TC	None	None	None	None	None

Abbreviations: ALT, alanine transaminases; anti-HBc, total hepatitis B core antibody; anti-HBe, hepatitis B e antibody; anti-HBs, hepatitis B surface antibody; AST, aspartate transaminase; 3TC, lamivudine; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NRTIs, nucleos(t)ide reverse transcriptase inhibitors; TDF, tenofovir disoproxil fumarate; UD, undetectable (<60 copies/mL).

^aAfter study entry, study visits were planned at weeks 4, 12, 24, 36, and 48. Given the retrospective nature of the analysis, stored samples for HBV testing were not available from all study visits; missing time points are blank.

^bPatient returned to standard of care triple ART at week 26 due to acute hepatitis and was recalled at weeks 36 and 105 for poststudy assessment.

^cPlasma HIV-1 RNA load in copies/mL.

^dCD4 count in cells/mm³.